# Robert P. Driscoll

> Robert P. Driscoll is a startup investor at BioAdvance. See 0 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: Angel Investor
- Fund: [BioAdvance](https://shizune.co/investors/profile/bioadvance)
- Last updated: Sep 2026

Robert P. Driscoll is a startup investor at BioAdvance. Mr. Driscoll brings twenty years of finance expertise in both multi-national corporations and venture-backed life sciences firms to BioAdvance. His career has focused on financial management reporting and consolidation, budgeting and forecasting, treasury management, and internal financial controls.Prior to joining BioAdvance Mr. Driscoll wascontroller with BioRexis Pharmaceutical Corporation (acquired by Pfizer Corporation). He also served as controller with Targeted Genetics Corporation (formerly Genovo, Inc.), and he held financial management positions with Nexell Therapeutics, Kulicke & Soffa Industries, Pfizer and ICI Americas. Mr. Driscoll holds a Masters of Science in financial management and a Bachelor of Science in accounting from Drexel University.

## Contacts

5 contacts available for Robert P. Driscoll: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/robert-p-driscoll?utm_source=investor_profile

## About BioAdvance

VC Fund · Philadelphia, United States

BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its new $50 million Greenhouse Fund. They invest in therapeutics, devices, diagnostics and platform technologies focused on human health.Since its first investments in 2003, BioAdvance has become one of the nation's leading investorsproviding pre-seed and seed-stage funding. To date they have committed more than $40 million to more than 50 seed-stage companies and 17 pre-seed companies. Their portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies.

5 contacts available at BioAdvance.

| Name | Title | Profile |
| --- | --- | --- |
| Shahram Hejazi | Partner | https://shizune.co/investors/profile/shahram-hejazi |
| Gregory Harriman | Partner and Chief Investment Officer | https://shizune.co/investors/profile/gregory-harriman |
| Jeff Edelson | Entrepreneur in Residence / Scientific Liason | https://shizune.co/investors/profile/jeff-edelson |
| Marnie McCoy | Program Director | https://shizune.co/investors/profile/marnie-mccoy |
| Robert P. Driscoll | Director of Finance | https://shizune.co/investors/profile/robert-p-driscoll |

## FAQ

### How do I contact Robert P. Driscoll?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co